*Refresh the page if the below document does not appear.
IPA gives clean chit to DOLO 650 mg makers Micro Labs
A report submitted to NPPA by Indian Pharmaceutical Alliance (IPA) said that the company was “following the practices according to the UCPMP guidelines” and found nothing incorrect.
Punjab facing drug shortage due to halt in pharma production
The state is experiencing a shortage of life saving drugs as the manufacturing units stopped the production. As per the reports, retailers are also asking high prices for drugs that are available and even NPPA is unable to manage the prices.
SII declares indigenously developed cevical cancer vaccine to hit the markets soon
CERVIVAC, is all set to be made available towards the end of this year and will cost around ₹ 200 – 400 a shot. It is indicated to be effective against at least four variants of HPV (Human Papilloma Virus).
Pharma stock returns adversely affected by US business growth
The lucrative US market has been experiencing flat for the past 12 months resulting in double digit negative return for the stocks. In the past few years, problems like constant pricing pressure and increasing regulatory scrutiny are some of the reasons for low returns.
Denmark based company sells marketing right to Zydus for Anemia treatment drug
Zydus acquired rights from Pharmacosmos to market MonoFerric (iron isomaltoside) Injections in India and Nepal. Since its launch, 28 million doses of the drug have been administered in about 30 countries including the USA.
Novartis' anti-inflammatory drug Cosentyx shows relief in patients with painful skin condition
The company stated that the drug is already approved for treating conditions such as psoriasis and arthritis, and now has shown positive results in trial patients suffering from hidradenitis suppurativa.
US FDA approves Bristol Myers' oral drug for moderate-to-severe plaque psoriasis
SOTYKTU, is a first of its kind drug for the
treatment of plaque psoriasis. It is an oral pill
which makes it more convenient to administer
as compared to its counterparts AbbVie’s Humira
and Amgen’s Enbrel, which are injectables.
